Lymphoma 2027: A Comprehensive Clinical Update From Diagnosis to Cellular Therapy

ACCME Credits. In-Person & Virtual Conference

February 26, 2027

8:00 AM - 4:30 PM (ET)

Program Overview
IN-PERSON & VIRTUAL CONFERENCE
The conference is designed to provide participants with a comprehensive review of the most important advances in lymphoma-related disease and to help advance participants in the field.

Video Access
Following the program, all registrants will have access to lecture video recordings for ONE month.

Learning Objectives

•Describe emerging molecular and genomic features of aggressive B-cell lymphomas and their implications for diagnosis, prognosis, and treatment selection.

•Apply current evidence-based strategies for the frontline and relapsed/refractory treatment of diffuse large B-cell lymphoma (DLBCL), including the appropriate use of novel agents.

•Evaluate contemporary treatment approaches for Hodgkin lymphoma, CLL, and indolent lymphomas, incorporating emerging therapies and patient-specific considerations.

•Recognize key diagnostic features and apply current therapeutic approaches for cutaneous and other T-cell lymphomas, including mycosis fungoides and Sézary syndrome.

•Assess the evolving role of cellular therapies, including CAR-T therapy and hematopoietic stem cell transplantation, in the management of patients with relapsed or refractory lymphoma.

Target Audience
This program is designed for physicians and other healthcare professionals involved in the diagnosis, treatment, and management of patients with lymphoma, including:

•Hematologists and medical oncologists

•Hematology/oncology fellows and trainees

•Internal medicine physicians

•Pathologists and hematopathologists

•Radiation oncologists

•Advanced practice providers (NPs and PAs) caring for patients with hematologic malignancies

•Other healthcare professionals involved in the multidisciplinary care of patients with lymphoma

Primary audience: Hematologists/oncologists, fellows, and other clinicians who manage patients with B-cell, T-cell, Hodgkin, and indolent lymphomas.

Format
Live Virtual Lectures, Panel Discussions, and Case-Based Learning

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Columbia University. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Professions in scope for this activity are listed below. Amedco Joint Accreditation #4008163.

Joint Accreditation Logo

Physicians
Amedco LLC designates this live activity for a maximum of x.x AMA PRA Category 1 Credits™ for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit.

Physician Assistants
The National Commission on Certification of Physician Assistant (NCCPA) states that AMA PRA Category 1 Credit™ are acceptable for continuing medical education requirements for recertification for PAs. Amedco LLC designates this live activity for a maximum of x.x AMA PRA Category 1 Credit™. PAs should claim only the credit commensurate with the extent of their participation in the activity.